申请人:Kissei Pharmaceutical Co., Ltd.
公开号:EP0309260A1
公开(公告)日:1989-03-29
This invention provides novel 4H-quinolizin-4-one compounds which exhibit a selective inhibitory activity against IgE-antibody formation, and have utility for treatment of diseases associated with IgE formation in mammals, such as allergic bronchial asthma, allergic rhinitis, atopic dermatitis, hypersensitiveness, and the like.
本发明提供的新型 4H-quinolizin-4-one 化合物对 IgE 抗体的形成具有选择性抑制活性,可用于治疗哺乳动物体内与 IgE 形成相关的疾病,如过敏性支气管哮喘、过敏性鼻炎、特应性皮炎、过敏性疾病等。